NCT06337162View on ClinicalTrials.gov

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2027

Study Completion Date

September 1, 2028

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

INCB099280

400 mg Tablet

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER